Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results, Beats Estimates By $0.23 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings data on Monday. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23, Zacks reports. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 earnings per share.

Krystal Biotech Stock Performance

KRYS stock opened at $186.89 on Tuesday. Krystal Biotech has a 1 year low of $125.85 and a 1 year high of $219.34. The firm has a market cap of $5.38 billion, a P/E ratio of 62.51 and a beta of 0.84. The stock has a 50-day simple moving average of $158.24 and a 200-day simple moving average of $175.31.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KRYS. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and a consensus price target of $210.00.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).